FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      Dashboard

      Novartis Halts Trials for RapaCabtagene Autoleucel in Autoimmune Diseases

      Novartis has announced a temporary pause in the screening, randomization, and treatment processes for its RapaCabtagene Autoleucel trials focused on autoimmune diseases. This decision affects ongoing clinical studies that are evaluating the safety and efficacy of the therapy.

      The company has not disclosed specific reasons for the pause, nor has it provided a timeline for when the trials might resume. Stakeholders are awaiting further information regarding the implications of this decision on the development of RapaCabtagene Autoleucel.

      RapaCabtagene Autoleucel is a novel therapy aimed at treating various autoimmune conditions, and its development has been closely monitored by the medical community. Novartis's action raises questions about the future of this treatment and its potential impact on patients.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud